|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Mark Andrew Rothera||Pres, CEO & Exec. Director||521,23k||N/D||1963|
|Dr. Giles V. Campion M.D.||Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director||436,2k||N/D||1954|
|Mr. Craig A. Tooman M.B.A., MBA||Chief Financial Officer||N/D||N/D||1966|
|Ms. Gem Gokmen Hopkins||Head of IR & Corp. Communications||N/D||N/D||N/D|
|Dr. Barbara A. Ruskin||Sr. VP, Gen. Counsel & Chief Patent Officer||N/D||N/D||1960|
|Ms. Linnea Elrington||VP & Head of HR||N/D||N/D||N/D|
|Dr. John Strafford Ph.D.||Sr. VP of Bus. Devel., Alliance Management & New Product Devel.||N/D||N/D||N/D|
|Mr. JÃ¸rgen Wittendorff||Sr. VP & Head of Manufacturing||N/D||N/D||N/D|
|Dr. Marie Wikstrom Lindholm Ph.D.||Sr. VP & Head of Molecular Design||N/D||N/D||N/D|
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
L'ISS Governance QualityScore di Silence Therapeutics plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.